Replies to post #113342 on Biotech Values

[DewDiligence]

…I've always been puzzled about how Sanofi (enox) and Teva (copax) could argue both that their patents are good but that at the same time that nobody else could possibly produce their product using only the descriptions provided in the patents. Seems to me like they should have an enablement or "best mode" problem, but then I'm no patent attorney.

This is an intriguing legal topic, but it’s no longer a practical concern for SNY because US patent protection for Lovenox is gone.